The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.
Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants / GALLI L; NOVELLI A; CHIAPPINI E; FALLANI P; M. DE MARTINO. - In: THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. - ISSN 0891-3668. - STAMPA. - 26:(2007), pp. 451-453. [10.1097/01.inf.0000261111.90075.4d]
Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.
GALLI, LUISA;NOVELLI, ANDREA;CHIAPPINI, ELENA;DE MARTINO, MAURIZIO
2007
Abstract
The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
